There have also been recent advances in immune checkpoint inhibitors in the treatment of BC: Immunotherapy in the form of the PD-1 inhibitor, pembrolizumab, has been approved for high-risk NMIBC patients who did not respond to BCG treatment [56]. Here, PDCD1 is linked to breast cancer.